Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Mette Marie Madsen
Major randomised controlled clinical trials (RCT) are considered to be the gold standard for providing clinical cardiologists with the evidence basis for decision-making. Interpretation of the results of these trials can be challenging, especially regarding the statistical analyses, which are sometimes of great complexity. On Monday 2nd September, we had a very interesting, educative, and interactive session where the audience was enlightened on the tricks and pitfalls of planning, conducting, and interpreting results from RCTs. MPH Sabina Murphy, Boston, US, first gave an interesting talk on interpreting superiority versus non-inferiority (NI) trials. Basically, superiority trials are designed to show that one treatment is better than the other, and are, in general, more simple in their design and analysis methods than non-inferiority trials, which are designed to show that a new treatment is “not unacceptably worse” than current therapy. Given this term “not unacceptably worse”, it is evident that a great deal of subjectivity has to be dealt with in choosing a clinically meaningful margin when designing the trial, since validity of any conclusions of NI trials depends on the choice of margins. Sabina Murphy provided us with some tricks on how to define these margins and gave examples of why NI trials, in spite of their complexity, unpopularity among some statisticians, and challenges, can and should be used (when placebo trials are non-ethical due to established gold standard therapy, to show that new treatment is safer, cheaper, more convenient). One other advantage of NI trials is that once non-inferiority is established, the design of the trials makes it feasible to evaluate for superiority.Another very important issue in analysing CRTs is choosing the right treatment analysis model. Prof. Jouven, Paris, France, gave a fine overview of intention to treat (ITT) versus per protocol (PP) analysis approaches. Dr. Jouven gave us several hypothetical examples illustrating what the two methods can provide. In general, ITT analysis better reflects the “real clinical world” and preserves the strength of randomisation of the patients in CRTs. Conversely, PP analysis – only analysing data from the patients fully adherent to their randomised treatment – does not maintain comparability of the patient groups generated from randomisation. Furthermore, we were presented with quite thought-provoking data showing that a large proportion of published trials that declare having used ITT actually do not implement this type of analysis when publishing the trial results, and the methods used to handle missing data are often not clarified. Missing outcome data is indeed quite challenging, but during his talk, Prof. Jouven gave some possible strategies on how to deal with this problem (statistical models, imputation, extreme case analysis etc).Finally, Prof. Pocock, London, GB, gave an illustrative presentation addressing endpoint analysis focusing on time-to-first-event versus all-event analysis. As an example, analyses of time to first heart failure hospitalisation versus all heart failure hospitalisations in some of the great trials evaluating the effect of treatment with statins and ARBs were used to show how alternative endpoint analyses can give rise to different interpretations of treatment effect. Using all-events, a gain in statistical power is achieved in trials with “repeat events” allowing a smaller sample size. An overview of the different statistical methods for analysing trials with repeat events was given and Prof. Pocock rounded off by pointing out the need for better agreement on methods of analysis, better and more graphical display and stressed the importance of sensitivity analysis and correct power calculations.A very enlightening session with complex topics made less abstruse. Look for yourself on ESC Congress 365.
Session Title: What went wrong with statistical analysis in major clinical trials? A session for the clinical cardiologist…